Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 51,955 | 57,967 | 65,226 | 71,194 | 74,876 |
| Other current assets | 3,143 | 3,475 | 3,518 | 2,098 | 1,285 |
| TOTAL | $55,678 | $62,517 | $68,744 | $74,457 | $77,111 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 2,334 | 1,998 | 2,003 | 1,987 | 2,366 |
| TOTAL | $2,334 | $1,998 | $2,003 | $1,987 | $2,366 |
| Total Assets | $58,012 | $64,515 | $70,747 | $76,444 | $79,477 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,536 | 2,010 | 1,165 | 679 | 1,561 |
| Accrued Expenses | 1,989 | 2,200 | 1,788 | 919 | 1,694 |
| Other current liabilities | 2,700 | 2,610 | 2,472 | 3,369 | 2,541 |
| TOTAL | $8,225 | $6,820 | $5,425 | $4,967 | $5,796 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $8,225 | $6,820 | $5,425 | $4,967 | $5,796 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 129,171 | 129,171 | 129,170 | 129,170 | 125,801 |
| Common Shares | 23,488 | 23,488 | 23,488 | 23,488 | 22,882 |
| Retained earnings | -235,625 | -226,933 | -218,510 | -211,792 | -205,445 |
| Other shareholders' equity | -475 | -475 | -475 | -475 | -475 |
| TOTAL | $49,787 | $57,695 | $65,322 | $71,477 | $73,681 |
| Total Liabilities And Equity | $58,012 | $64,515 | $70,747 | $76,444 | $79,477 |